Denali Therapeutics Inc. Investment Income, Amortization of Discount
Denali Therapeutics Inc. (DNLI) reported Investment Income, Amortization of Discount of $2.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfDiscount · last filed 2026-08-06
- Denali Therapeutics Inc. investment income, amortization of discount for the quarter ending 2026-06-30 was $1.45M, a 46.42% decline year-over-year.
- Denali Therapeutics Inc. investment income, amortization of discount for the quarter ending 2026-03-31 was $1.26M, a 67.62% decline year-over-year.
- Denali Therapeutics Inc. investment income, amortization of discount for the quarter ending 2025-12-31 was $1.64M, a 73.37% decline year-over-year.
- Denali Therapeutics Inc. investment income, amortization of discount for the quarter ending 2025-09-30 was $2.03M, a 75.82% decline year-over-year.
- Denali Therapeutics Inc. investment income, amortization of discount for fiscal 2025 was $10.25M, a 70.80% decline from fiscal 2024.
- Denali Therapeutics Inc. investment income, amortization of discount for fiscal 2024 was $35.12M, a 20.10% decline from fiscal 2023.
- Denali Therapeutics Inc. investment income, amortization of discount for fiscal 2023 was $43.95M, a 2584.91% increase from fiscal 2022.
- Denali Therapeutics Inc. investment income, amortization of discount for fiscal 2022 was $1.64M.
| Period end | Investment Income, Amortization of Discount 3 month | Investment Income, Amortization of Discount 6 month | Investment Income, Amortization of Discount 9 month | Investment Income, Amortization of Discount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.70M 10-Q · filed 2026-08-06 | $4.35M derived: sum of 3 quarters · filed 2026-08-06 | $6.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.26M 10-Q · filed 2026-05-07 | $2.90M derived: sum of 2 quarters · filed 2026-05-07 | $4.93M derived: sum of 3 quarters · filed 2026-05-07 | $7.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.67M derived: sum of 2 quarters · filed 2026-02-26 | $6.37M derived: sum of 3 quarters · filed 2026-08-06 | $10.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.72M derived: sum of 2 quarters · filed 2026-08-06 | $8.61M 10-Q · filed 2025-11-06 | $14.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.58M 10-Q · filed 2026-08-06 | $12.75M derived: sum of 3 quarters · filed 2026-08-06 | $21.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.89M 10-Q · filed 2026-05-07 | $10.05M derived: sum of 2 quarters · filed 2026-05-07 | $18.43M derived: sum of 3 quarters · filed 2026-05-07 | $28.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.54M derived: sum of 2 quarters · filed 2026-02-26 | $24.60M derived: sum of 3 quarters · filed 2026-02-26 | $35.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.44M derived: sum of 2 quarters · filed 2025-11-06 | $28.95M 10-Q · filed 2025-11-06 | $41.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $20.57M 10-Q · filed 2025-08-11 | $32.82M derived: sum of 3 quarters · filed 2026-02-26 | $45.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.52M 10-Q · filed 2025-05-06 | $22.76M derived: sum of 2 quarters · filed 2026-02-26 | $35.08M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.57M derived: sum of 2 quarters · filed 2026-02-26 | $43.95M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $12.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $31.71M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $19.39M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $1.64M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |